State Street’s Argos Therapeutics, Inc. ARGS Stock Holding History

State Street’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-595	Closed	-$1K	–	3852
2017 Q4	$1K	Hold	595	–	–	﹤0.01%	3728
2017 Q3	$2K	Hold	595	–	–	﹤0.01%	3760
2017 Q2	$4K	Sell	595 -8,615	-94%	-$73.4K	﹤0.01%	3697
2017 Q1	$82K	Buy	9,210 +335	+4%	+$21.2K	﹤0.01%	3549
2016 Q4	$870K	Buy	8,875 +932	+12%	+$87.2K	﹤0.01%	3305
2016 Q3	$787K	Buy	7,943 +1,893	+31%	+$198K	﹤0.01%	3234
2016 Q2	$741K	Buy	+6,050	New	+$808K	﹤0.01%	3333
2014 Q2	–	Sell	-1,325	Closed	-$265K	–	3747
2014 Q1	$265K	Buy	+1,325	New	+$265K	﹤0.01%	3431

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

State Street's ARGS Position: Q1 2018 in Review

State Street sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 595 shares — an estimated $1K sold.

State Street first reported a position in ARGS in Q1 2014 and held it in 8 quarters. The position peaked at $870K in Q4 2016. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

State Street reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
State Street sold 595 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $1K.
State Street first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 8 quarters.
State Street's Argos Therapeutics, Inc. position peaked at $870K in Q4 2016.
16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on State Street's 13F filing for Q1 2018, filed 15 May 2018.